Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2020 - 2026)

Xilio Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $163.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 57.63% year-over-year to $163.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $585.7 million (up 72.6% YoY) and the FY2025 annual result came in at $154.7 million, up 117.64% from the prior year.
• Liabilities and Shareholders Equity climbed to $163.5 million in Q1 2026 per XLO's latest filing, from $154.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $196.4 million in Q1 2022 and troughed at $60.9 million in Q4 2023.
• A 5-year average of $118.9 million and a median of $111.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 56.22% in 2023, then jumped 117.64% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $139.2 million in 2022, then tumbled by 56.22% to $60.9 million in 2023, then gained by 16.66% to $71.1 million in 2024, then surged by 117.64% to $154.7 million in 2025, then advanced by 5.69% to $163.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $163.5 million, $154.7 million, and $133.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.